| Scrip Code | 540222 |
|---|---|
| NSE Symbol | LAURUSLABS |
| MSEI Symbol | NOTLISTED |
| ISIN | INE947Q01028 |
| Name of company | LAURUS LABS LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 23-01-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 09-01-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Third quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | Manufacturer of Generics API, Generics FDF, Synthesis and Bio Technology |
| Start date and time of board meeting | 23-01-2026 14:00:00 |
| End date and time of board meeting | 23-01-2026 14:40:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| Not Applicable. | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 1,50,942.00 | 4,50,877.00 | |
| Other income | 1,437.00 | 6,434.00 | |
| Total income | 1,52,379.00 | 4,57,311.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 64,972.00 | 1,86,701.00 |
| (b) | Purchases of stock-in-trade | 5,512.00 | 12,432.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (7,917.00) | (10,593.00) |
| (d) | Employee benefit expense | 19,629.00 | 55,850.00 |
| (e) | Finance costs | 3,148.00 | 10,905.00 |
| (f) | Depreciation, depletion and amortisation expense | 9,431.00 | 28,347.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 34,160.00 | 1,00,197.00 |
| Total other expenses | 34,160.00 | 1,00,197.00 | |
| Total expenses | 1,28,935.00 | 3,83,839.00 | |
| 3 | Total profit before exceptional items and tax | 23,444.00 | 73,472.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 23,444.00 | 73,472.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 6,903.00 | 21,662.00 |
| 8 | Deferred tax | (967.00) | (3,059.00) |
| 9 | Total tax expenses | 5,936.00 | 18,603.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 17,508.00 | 54,869.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 17,508.00 | 54,869.00 |
| 17 | Other comprehensive income net of taxes | (172.00) | (210.00) |
| 18 | Total Comprehensive Income for the period | 17,336.00 | 54,659.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 10,797.00 | 10,797.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 3.25 | 10.17 | |
| Diluted earnings (loss) per share from continuing operations | 3.23 | 10.15 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 3.25 | 10.17 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 3.23 | 10.15 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1.The above standalone unaudited financial results of Laurus Labs Limited has been reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 23 2026. The statutory auditors of the Company have carried out a limited review on standalone financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31 2025 2.These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India. 3.The Company is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments. 4.The Board of Directors of the Company, in its meeting held on August 21 2025 approved the proposed Composite Scheme of Arrangement for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi under section 230 and 232 of the Companies Act 2013 and other applicable provisions of the Act and the rules made thereunder. The Company has filed a petition with NCLT on October 11 2025. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01 2026 or such other date as the NCLT may approve. Pending such approval, the standalone financial results of the Company for the quarter and nine months ended December 31 2025 quarter ended September 30 2025 quarter and nine months ended December 31 2024 and year ended March 31 2025 are presented without giving effect to the said merger. 5.During the quarter ended December 31 2025 the Company allotted 31683 equity shares of Rs 2 each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme 6.The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019 Code on Social Security 2020 Industrial Relation Code 2020 and Occupational Safety Health and Working Condition Code 2020 collectively referred to as the New Labour Codes. These Codes have been made effective from November 21, 2025. The corresponding supporting rules under these codes are yet to be notified.The Company is in the process of evaluating the full impact of these new labour codes announced. The Company continues to monitor the finalisation of Central or State Rules and Clarifications from the Government on the other aspects of New Labour Code. The Company has estimated and accounted for incremental liability for employees of Rs 8 Crores which is not material to the financial results. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-10-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 31-12-2025 | 31-12-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement gains/(losses) on defined benefit plans | (230.00) | (281.00) |
| Total Amount of items that will not be reclassified to profit and loss | (230.00) | (281.00) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (58.00) | (71.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (172.00) | (210.00) |